To test whether ALKAL2‐driven NB was sensitive to ALK TKI treatment in vivo, we treated NB tumours arising in Rosa26_Alkal2;Th‐MYCN mice with lorlatinib (10 mg/kg body weight, 2× per day) for a period of 14 days and monitored tumour growth by ultrasound. This evidence concerns the gene ALK and neoplasm.